Taurus Vascular is one step closer to stopping abdominal aortic aneurysms for good. Photo courtesy of TNVC

A Houston biotech company has won the Texas A&M New Ventures Competition (TNVC). Taurus Vascular took home $30,000 for its first-place victory.

Taurus Vascular is working on a new solution to stopping abdominal aortic aneurysms (AAA) before they rupture and become potentially fatal. The company arose out of the TMC Innovation Biodesign Program. Fellows Matthew Kuhn and Melanie Lowther had a year to bring a company to fruition. The highly qualified team can boast of Kuhn’s more than 40 patents and Lowther’s former role as director of entrepreneurship and innovation at Texas Children’s Hospital.

The competition’s intense process included presenting to commercialization experts across several rounds. In fact, vetting takes four months and includes coaching to help competitors thrive in their pitches.

“As we celebrate the tenth year of the Texas A&M New Ventures Competition, we recognize the significant economic impact these startups have across Texas and their worldwide societal contributions,” says Chris Scotti, TNVC chair, in a news release. “Looking ahead, we are excited to continue fostering innovation and supporting science and engineering-based companies that drive progress and create lasting change.”

In its decade of competitions, TNVC has awarded almost $4 million prizes to startups. This year alone, 27 awards were distributed. Those included investment capital, consulting, legal and engineering services, and other types of support tailored to the winners’ needs.

“We are honored to have won first place at the Texas New Ventures Competition. Competing alongside so many outstanding companies and talented founders makes this recognition even more meaningful and reflects the dedication and hard work of our team at Taurus Vascular,” Kuhn says in a press release. “The financial support and increased visibility from this win will be pivotal for our growth, unlocking new opportunities and partnerships.

"This award strengthens our belief in our mission of reducing endoleak risks in endovascular aortic aneurysm repair and making a positive impact on patient care," he continues. "We are also grateful to Biotex for choosing us as a recipient for their sponsored prize and eagerly anticipate collaborating with them in the next phase of our technology’s development.”

Fewer than 20 percent of patients whose AAAs rupture survive. Kuhn told InnovationMap last year that he hopes to commercialize his technology by 2030. This competition brings patients closer to one day having far better odds when contending with a AAA.

A new innovation out of the Texas Medical Center's Biodesign Program is enhancing efficacy of a life-saving aortic aneurysm rupture procedure. Photo via Getty Images

Houston biodesign innovators ready to spin out startup with life-saving vascular tech

heartbreak healers

Yes, you can die of a broken heart — although it's not in the hyperbolic way you might be thinking. Fewer than 20 percent of people who have an aortic aneurysm rupture survive the event. But aortic aneurysms can be treated if they’re caught before they burst. A new Houston company is devoted to a novel solution to helping patients with abdominal aortic aneurysms (AAA).

That company is Taurus Vascular. As part of the current class of the TMC Innovation Biodesign Program, fellows Matthew Kuhn and Melanie Lowther were tasked with creating a biomedical company in a year. The founders started their journey last August. At the end of this month, they'll be kicked out of the nest, Kuhn tells InnovationMap. Taurus is also in Rice University's 2023 cohort of OwlSpark, an ongoing summer program for startups founders from the Rice community.

Kuhn is a biomedical engineer who just scored his forty-fifth patent. The CEO says that he hit it off quickly with his co-founder and COO, Lowther, former director entrepreneurship and innovation at Texas Children’s Hospital.

Matthew Kuhn and Melanie Lowther co-founded Taurus Vascular as TMC Biodesign fellows. Photos via taurusvascular.com

Members of the Biodesign Program are paid a livable stipend to devote themselves fully to creating a pioneering company. Kuhn says that he became interested in finding a more effective way to heal AAAs during his four and a half years as a project leader at the Center for Device Innovation at the Texas Medical Center.

“It was ripe for innovation and we landed on a concept of some merit,” he says.

The current standard of care for AAAs is EVAR, or endovascular aneurysm repair, in which a surgeon inserts a stent to relieve pressure on the aneurysm.

“It used to be if you had a AAA, you had a gnarly procedure,” he says, which included a large incision across the abdomen. EVAR eliminated that, but its problem is that it often results in endoleaks. As many as 20 percent of patients need another EVAR within five years.

Taurus Vascular’s technology improves on EVAR by placing a self-deploying stent to create a drainage pathway between the high-pressure aneurysm sac and a low-pressure nearby vein — mitigating the adverse impact of endoleaks that would otherwise cause the aneurysm to continue to grow. The simple solution will allow patients to live longer, healthier lives after their procedure.

Kuhn says that being in Houston has been and will continue to be instrumental in his company’s success. Part of that, of course, is his relatively cosseted status as a founder in the Innovation Biodesign Program. But he says that the industry as a whole has become almost like a family.

“It feels very different from startup life for other industries where it feels competitive,” he explains. "You have to be a little crazy to start a medical device company and there’s a sense that we’re all in the same boat. People are so generous with their time to share resources. I feels like I have 100 co-founders."

Following the end of Taurus Vascular’s time in the program that helped conceived it, its founders will remain in the same building, continuing to work to support their technology. The next step is raising a seed round that will pay for the company’s chronic animal studies. Because Taurus Vascular is producing a Class III medical device, its approval process to get to market is the most stringent the FDA has.

The goal is to be commercial by 2030, says Kuhn. By then, Taurus Vascular will have healed many a heart.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

6+ can't-miss Houston business and innovation events in March

where to be

Editor's note: March brings the return of some of Houston’s signature innovation events, plus insightful talks and celebrations in honor of Women's History Month. Here’s what not to miss and how to register. Please note: this article may be updated to include additional event listings.

March 3-4 — Houston MedTech Rodeo

Head to Armadillo Palace for the annual Houston MedTech Rodeo. The casual, Texas-themed conference brings together 350 medtech professionals who come from over 10 countries and 15 states to highlight Houston's growing medtech ecosystem. The event will feature panel discussions, startup showcases, networking sessions—plus, armadillo races, mechanical bull riding and live country music.

The event begins March 3 at Armadillo Palace on Kirby Drive. Register here.

March 4 – Humans of Healthcare

Houston Methodist Center for Innovation will present its new quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on IT. The panel will be moderated by Houston Methodist's Director of Innovation Murat Uralkan.

The event is Wednesday, March 4, from 5-6 p.m. at the Ion. Register here.

March 5 — The Future of Women in STEM

Celebrate Women's History Month at SUPERGirls SHINE Foundation's The Future of Women in STEM event, presented in partnership with the Ion. The event will feature speakers and panelists, including Kalila Winters Hines, senior public affairs advisor for Holland & Knight; Dr. Natacha Chough, NASA Johnson Space Center Flight Surgeon; and Andrea Course, rocket scientist and founder of Course Investments.

The event is Thursday, March 5, from 8:30-10 a.m. at the Ion. Register here.

March 10-12 — World Hydrogen & Carbon Americas

S&P Global Energy brings together two leading events—Carbon Management Americas and World Hydrogen North America—to form a new must-attend event for those in the hydrogen and carbon industries. More than 800 senior leaders from across the energy value chain will attend this event featuring immersive roundtable discussions, hands-on training, real-world case studies and unparalleled networking opportunities.

This event begins March 10 at the Marriott Marquis Houston. Register here.

March 20 — Ideas to Impact Accelerator Graduation and Showcase

Join Impact Hub Houston as it celebrates its inaugural Ideas to Impact Accelerator cohort. The 16-week accelerator is designed to help early-stage entrepreneurs validate their business models, strengthen confidence and gain traction. Hear short pitches and network with founders and mentors.

The event is Friday, March 20, from noon-2 p.m. at the Ion. Register here.

March 23-27 — CERAWeek 2026

CERAWeek 2026 will focus on "Convergence and Competition: Energy, Technology and Geopolitics." The industry's foremost thought leaders will convene in Houston to cultivate relationships and exchange transformative ideas during the annual event. CERAWeek 2026 will explore breakthroughs, cross-industry connections and powerful partnerships that are accelerating the transformation of the global energy system. 2026 highlights include an appearance by tech magnate Bill Gates.

This event begins March 23. Register here.

March 24-25 — 2026 Energy Venture Day and Pitch Competition

The Energy Venture Day and Pitch Competition, co-hosted by the Rice Alliance, Ion, HETI and TEX-E, offers two days of exciting pitches from more than 40 global energy ventures that are transforming the industry. On Tuesday, March 24, you can attend a fast-paced pitch preview event at the Ion, followed by the official Pitch Competition at 1 pm on Wednesday, March 25, at the George R. Brown Convention Center.

March 30-April 4 — H-Town Roundup

Celebrate innovation, entrepreneurship and collaboration at Houston Exponential's sixth-annual H-Town Roundup. During the free event series, previously known as Houston Tech Rodeo, attendees can expect insightful talks, workshops and networking events at venues across the city.

This event begins Monday, March 30. Register here.

Intuitive Machines secures $175M equity investment to fuel growth

space funding

Houston-based space infrastructure and services company Intuitive Machines has secured a $175 million equity investment from unidentified institutional investors. The investors received shares of Class A stock in exchange for their funding.

Publicly held Intuitive Machines (Nasdaq: LUNR) says it plans to use the capital to help build revenue and invest in technology, including communications and data-processing networks.

“We are building a scalable infrastructure platform from low-Earth orbit to the moon and into deep space,” Intuitive Machines CEO Steve Altemus said in a news release. “With this investment, we can accelerate the integration of the combined company’s collective capabilities to deliver next-generation data, communications, and space-based infrastructure services.”

Intuitive Machines says the $175 million investment will improve its ability to secure deals for satellite systems, the proposed Golden Dome missile defense system and the proposed Mars telecommunications orbiter.

As the company pursues those deals, it’s seeking partners to develop space-based data centers.

The $175 million equity stake comes on the heels of Intuitive Machines completing its $800 million cash-and-stock purchase of Lanteris Space Systems. Intuitive Machines bought the satellite manufacturer from private equity firm Advent International.

In the third quarter, which ended Sept. 30, Intuitive Machines posted a $10 million net loss on revenue of $52.4 million.